Mark Litton

Chief Executive Officer at LEONABIO, INC.

Net worth: 422 852 $ as of 2026-07-30

58 year

69 connections

Health Technology

Consumer Services

Commercial Services

Profile

Mark J.
Litton was the founder of Lundbeck Seattle BioPharmaceuticals, Inc., founded in 2004, where the titles held included Secretary, Treasurer & Chief Business Officer from 2014 to 2018.
Current jobs include President, Chief Executive Officer & Director at LeonaBio, Inc. since 2021, and Director at Lumen Bioscience, Inc. Former jobs include Manager-Business Development at Sirna Therapeutics, Inc. from 1997 to 1999; Vice President-Business Development at Celltech Group Plc from 1999 to 2004; Vice President-Business Development at Chiroscience Group Plc; Research Associate at DNAX Research, Inc. from 1991 to 1994; and President & Chief Operating Officer at Alpine Immune Sciences, Inc. from 2018 to 2019.
Education history includes an MBA from Santa Clara University in 1994, an undergraduate degree from the University of California, Santa Cruz in 1990, and a doctorate from the University of Stockholm in 1997.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
LEONABIO, INC. 0.64%	2026-04-30	59,894 ( 0.64% )	422 852 $	2026-07-30

Mark Litton active positions

Companies	Position	Start
LEONABIO, INC.	Chief Executive Officer	2021-06-15
Lumen Bioscience, Inc. Lumen Bioscience, Inc. BiotechnologyHealth Technology Develops biologic drug platform	Director/Board Member	-

All active positions of Mark Litton

Former positions of Mark Litton

Companies	Position	End
ALPINE IMMUNE SCIENCES, INC.	President	2019-04-15
ALDER BIOPHARMACEUTICALS, INC.	Founder	2018-07-31
Celltech Group Plc Celltech Group Plc BiotechnologyHealth Technology Develops and manufactures pharmaceuticals	Corporate Officer/Principal	2003-12-31
Sirna Therapeutics, Inc. Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides and develops pharmaceutical products	Corporate Officer/Principal	1998-12-31
DNAX Research, Inc.	Corporate Officer/Principal	1993-12-31

See the detail of Mark Litton's experience

Training of Mark Litton

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Litton's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	11
Sirna Therapeutics, Inc. Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides and develops pharmaceutical products	Commercial Services
Celltech Group Plc Celltech Group Plc BiotechnologyHealth Technology Develops and manufactures pharmaceuticals	Health Technology
LeonaBio, Inc. LeonaBio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company	Health Technology
Chiroscience Group Plc Chiroscience Group Plc Miscellaneous Commercial ServicesCommercial Services Research based pharmaceutical group	Commercial Services
Santa Clara University Santa Clara University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of California, Santa Cruz University of California, Santa Cruz Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Stockholm University of Stockholm Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Lundbeck Seattle BioPharmaceuticals, Inc. Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases	Health Technology
DNAX Research, Inc.
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as an bio pharmaceutical company that develops immunotherapies for autoimmune and inflammatory diseases	Health Technology
Lumen Bioscience, Inc. Lumen Bioscience, Inc. BiotechnologyHealth Technology Develops biologic drug platform	Health Technology